|Bid||2.1400 x 3000|
|Ask||2.7000 x 900|
|Day's Range||2.3197 - 2.5600|
|52 Week Range||1.5000 - 16.7400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
LOS ALTOS, Calif., August 15, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
LOS ALTOS, Calif., July 19, 2022--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.